What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Diabetes mellitus
- Disease
His scientific interests lie mostly in Diabetes mellitus, Internal medicine, Endocrinology, Type 2 diabetes and Obesity.
Jonathan E. Shaw combines subjects such as Epidemiology, Incidence and Risk factor with his study of Diabetes mellitus.
His studies deal with areas such as Gastroenterology and Cross-sectional study as well as Endocrinology.
The various areas that he examines in his Type 2 diabetes study include Randomized controlled trial, Surgery, Glycemic, Insulin resistance and Developing country.
His study in Obesity is interdisciplinary in nature, drawing from both Body mass index, Gerontology and Public health.
Environmental health, Urbanization and MEDLINE is closely connected to Global health in his research, which is encompassed under the umbrella topic of Gerontology.
His most cited work include:
- The metabolic syndrome—a new worldwide definition (6945 citations)
- Global estimates of the prevalence of diabetes for 2010 and 2030. (4762 citations)
- Global and societal implications of the diabetes epidemic (4743 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Diabetes mellitus, Internal medicine, Type 2 diabetes, Obesity and Endocrinology.
In his study, Cohort study is inextricably linked to Gerontology, which falls within the broad field of Diabetes mellitus.
His Internal medicine study integrates concerns from other disciplines, such as Surgery and Cardiology.
The concepts of his Type 2 diabetes study are interwoven with issues in Kidney disease, Intensive care medicine, Type 1 diabetes, Pediatrics and Type 2 Diabetes Mellitus.
He has included themes like Body mass index, Epidemiology and Environmental health in his Obesity study.
His Body mass index study combines topics from a wide range of disciplines, such as Cross-sectional study, Physical therapy and Cohort.
He most often published in these fields:
- Diabetes mellitus (64.50%)
- Internal medicine (50.19%)
- Type 2 diabetes (32.18%)
What were the highlights of his more recent work (between 2017-2021)?
- Diabetes mellitus (64.50%)
- Type 2 diabetes (32.18%)
- Internal medicine (50.19%)
In recent papers he was focusing on the following fields of study:
Jonathan E. Shaw focuses on Diabetes mellitus, Type 2 diabetes, Internal medicine, Obesity and Incidence.
Jonathan E. Shaw interconnects Disease, Pediatrics and Kidney disease in the investigation of issues within Diabetes mellitus.
His studies in Type 2 diabetes integrate themes in fields like Metformin, Poisson regression, National Death Index, Obstetrics and Gestational diabetes.
His work in Internal medicine addresses issues such as Dulaglutide, which are connected to fields such as Placebo.
His Obesity research is multidisciplinary, incorporating perspectives in Body mass index, Logistic regression, Environmental health, Cohort and Australian diabetes.
Jonathan E. Shaw combines subjects such as Population Risk, Secular variation and MEDLINE with his study of Incidence.
Between 2017 and 2021, his most popular works were:
- IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. (1981 citations)
- Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. (1031 citations)
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (593 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Disease
Jonathan E. Shaw spends much of his time researching Diabetes mellitus, Type 2 diabetes, Internal medicine, Incidence and Obesity.
His Diabetes mellitus study incorporates themes from Cause of death, Pediatrics and Age of onset.
The Type 2 diabetes study combines topics in areas such as Clinical trial, Poisson regression, Randomized controlled trial, National Death Index and Sulfonylurea.
In his research, Placebo is intimately related to Dulaglutide, which falls under the overarching field of Internal medicine.
His Incidence research is multidisciplinary, incorporating elements of Blood lipids, Cholesterol, Absolute risk reduction and Disease.
His Obesity study combines topics in areas such as Body mass index, Retrospective cohort study, Cross-sectional study and Australian diabetes.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
